1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,740 | 3,140 | 10:10 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | Stocks in Play: HLS Therapeutics Inc. | - | Baystreet.ca | ||
| 14.04. | HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference | 2 | CNW | ||
| 16.03. | HLS Therapeutics. Buy, Sell or Hold? | 2 | Cantech Letter | ||
| 12.03. | HLS Therapeutics GAAP EPS of -$0.04, revenue of $15.1M | 1 | Seeking Alpha | ||
| 12.03. | Stocks in Play: HLS Therapeutics Inc. | - | Baystreet.ca | ||
| 12.03. | HLS Therapeutics 2025 slides: cash flow jumps 114% amid pivot | 1 | Investing.com | ||
| 12.03. | HLS Therapeutics Announces Fiscal 2025 Financial Results | 2 | CNW | ||
| 05.03. | HLS Therapeutics Inc: HLS Therapeutics launches Nilemdo in Canada | 2 | Stockwatch | ||
| HLS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.03. | HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease | 1 | CNW | ||
| 26.02. | HLS Therapeutics Inc: HLS Therapeutics to release 2025 results March 12 | 1 | Stockwatch | ||
| 26.02. | HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call | 2 | CNW | ||
| 26.12.25 | Should you sell your HLS Therapeutics stock? | 3 | Cantech Letter | ||
| 18.11.25 | HLS Therapeutics Inc: HLS gets approval for Nilemdo; Nezlizet needs more data | 1 | Stockwatch | ||
| 18.11.25 | HLS Therapeutics Announces Health Canada Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease | 3 | CNW | ||
| 18.11.25 | Esperion Therapeutics, Inc.: Esperion Partner HLS Therapeutics Announces Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease | 213 | GlobeNewswire (Europe) | ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization... ► Artikel lesen | |
| 13.11.25 | HLS Therapeutics GAAP EPS of -$0.12, revenue of $13.5M | 2 | Seeking Alpha | ||
| 13.11.25 | HLS Therapeutics Announces Q3 2025 Financial Results | 1 | CNW |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,35 | -0,75 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| EVOTEC | 5,050 | +0,90 % | Evotec: Gewinnmitnahme! | ||
| MODERNA | 38,830 | -0,83 % | Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 | ||
| VALNEVA | 2,326 | -0,56 % | Valneva Announces the Successful Completion of an €84 million Reserved Offering | Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ("Valneva" or the "Company"), a specialty... ► Artikel lesen | |
| NOVAVAX | 6,740 | -1,46 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| NANOREPRO | 1,560 | +1,96 % | Original-Research: NanoRepro AG (von NuWays AG): KAUFEN | Original-Research: NanoRepro AG - von NuWays AG
23.04.2026 / 09:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| OCUGEN | 1,458 | +0,41 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,309 | +1,31 % | BioNxt setzt auf fortschrittliche Drug-Delivery-Strategie und psychedelische Wirkstoffbibliothek im aufstrebenden Therapeutika-Markt bei wachsender globaler Dynamik | VANCOUVER, BC / ACCESS Newswire /
28. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| MAINZ BIOMED | 0,469 | 0,00 % | Quantum Cyber N.V. - 8-K, Current Report | ||
| INFLARX | 1,600 | -5,44 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| ATAIBECKLEY | 3,560 | +1,14 % | Psychedelika im Aufwind - AtaiBeckley und Emyria im Fokus | ||
| IMMATICS | 9,470 | -1,30 % | TD Cowen initiates Immatics stock coverage with buy rating | ||
| ORAGENICS | 6,000 | 0,00 % | Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal... ► Artikel lesen | |
| GLOW LIFETECH | 0,026 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,528 | +1,58 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen |
HLS THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,740 Euro und damit +1,48 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HLS THERAPEUTICS INC finden Sie auf Wallstreet Online.